For medtechs, the short term has become complicated almost beyond imagination, with markets and trade disrupted by geopolitical conflict, tariffs, and supply chain difficulties and even the Suez Canal
Before life sciences companies reported first-quarter earnings, a jump in sales might have been expected as companies and patients stocked up ahead of tariffs. But in the event, this was less pronounc
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re